Form 4: Predictive Oncology Director Granted 64,680 RSUs

Predictive Oncology Inc. Director Gregory St. Clair received a grant of 64,680 restricted stock units, vesting fully on October 31, 2025.

Summary

• Director Gregory St. Clair of Predictive Oncology Inc. (POAI) was granted 64,680 restricted stock units (RSUs).
• Each RSU represents the right to receive one share of common stock upon vesting.
• The RSUs will vest in full on October 31, 2025, contingent upon continued service through that date.
• Following this transaction, Director St. Clair beneficially owns a total of 85,882 shares of common stock.

Sentiment

Score: 7

Explanation: The grant of equity to a director is generally viewed positively as it aligns the director's interests with those of the shareholders, incentivizing long-term performance. This is a routine compensation event and does not indicate operational issues.

Positives

• The grant of restricted stock units aligns the director's financial interests with those of the shareholders, incentivizing long-term company performance.
• Equity compensation is a standard practice for retaining and motivating key personnel and board members.

Future Outlook

The filing indicates that the granted restricted stock units are scheduled to vest in full on October 31, 2025, provided the director continues their service through that date.

Industry Context

The grant of restricted stock units to a director is a common and widely accepted practice in the biotechnology and broader corporate sectors for executive and board compensation. It serves to align the interests of the director with the long-term performance of the company and its shareholders.

Comparison to Industry Standards

• Equity grants, such as Restricted Stock Units (RSUs), are a standard component of director compensation packages across various industries, including the life sciences sector where Predictive Oncology operates.
• The practice is consistent with corporate governance best practices aimed at fostering long-term commitment and performance alignment, similar to compensation structures seen at comparable small-cap biotech firms.

Related Party Transactions

• The grant of restricted stock units to Director Gregory St. Clair constitutes a related party transaction, as it involves compensation from the company to a member of its board of directors. This is a standard compensation mechanism.

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with shareholder value creation, potentially leading to more focused long-term decision-making.
• Employees: No direct impact on general employees is indicated by this filing.

Next Steps

• The restricted stock units are scheduled to vest in full on October 31, 2025, subject to continued service.

Key Dates

Recommendation

This Form 4 filing details a standard equity grant to a director, which is a positive for corporate governance and aligns management interests with shareholders. However, it does not contain information significant enough to alter a fundamental investment thesis or warrant a strong buy/sell recommendation based solely on this disclosure. Investors should consider broader company fundamentals and market conditions.

Keywords

Predictive Oncology, POAI, Gregory St. Clair, Restricted Stock Units, RSUs, Director Compensation, Equity Grant, Insider Ownership, SEC Form 4